PDF
(Download)
|
- Bacopa (Bacopa monnieri)
- KeenMind®
- Cognition
|
Date:
02-28-2014 | HC# 101353-491
|
Re: Clinical Review of the Cognitive Effects of Bacopa
Stough
C, Scholey A, Cropley V, et al. Examining the cognitive effects of a special extract
of Bacopa monniera [sic] (CDRI 08: KeenMind): A review of ten
years of research at Swinburne University. J
Pharm Pharm Sci. 2013;16(2):254-258.
The
purpose of this review article was to summarize the clinical research
evaluating bacopa (Bacopa monnieri)
and more specifically KeenMind® (CDRI 08; Flordis; St. Leonards,
NSW, Australia) for treating neurological disorders. KeenMind is an extract of
bacopa that is standardized to contain 55% bacosides. Bacopa is used in
traditional Ayurvedic medicine for treating memory decline, inflammation, pain,
pyrexia (fever), epilepsy, and it is used as a sedative. The authors point out
that other products cannot be expected to have the same efficacy as they have been
grown and extracted under different conditions and will have their own unique chemical
compositions.
Experimental
evidence indicates that bacopa improves motor learning, acquisition, and
retention; delays extinction of newly acquired behavior; has anti-inflammatory,
anxiolytic, and antidepressant actions; dilates blood vessels; and has adaptogenic
activity. The exact mechanism of action is unknown but possible contributing effects
may include direct procholinergic action, antioxidant (flavonoid) capacity,
metal chelation, anti-inflammatory effects, increased blood circulation, adaptogenic
activity, and removal of beta-amyloid deposits.
The
authors briefly summarize six studies conducted at their research facility.
Three randomized, placebo-controlled studies evaluated healthy individuals who
received 320 mg KeenMind for 90 days. A battery of cognitive testing revealed
that KeenMind improved information processing speed and verbal learning, and
decreased anxiety compared to placebo. One study showed that bacopa and the
pharmaceutical modafinil produce a similar magnitude of cognitive improvement,
but at different rates (modafinil was quicker). The acute cognitive-enhancing
benefits of KeenMind were evaluated in two double-blind, placebo-controlled
crossover studies where healthy subjects received 320 mg or 640 mg of KeenMind prior
to conducting cognitive tasks. KeenMind improved divided attention compared
with placebo, indicating that KeenMind can work acutely, as well as over a
longer time frame.
The authors
hypothesize that the mechanism of action for acute and chronic effects are
different. Acute effects
may include direct neurotransmitter changes, increase in blood flow, or
increases in energy metabolism. The mechanisms associated with improvement in
inflammation and antioxidant status, reduction in beta-amyloid and increases in
metal chelation are likely to occur over longer time frames and be more
suitable to improving cognitive function in abnormal brain states or in the
ageing brain using chronic treatment.
The
authors briefly summarize five studies that are underway. As the brain ages,
cognitive and pathological changes occur. The authors are conducting a
randomized, double-blind, placebo-controlled study of 310 subjects receiving
320 mg/day KeenMind or placebo for 12 months. The primary aim is to investigate
the effects of KeenMind on cognitive performance. The secondary aims are to
explore the time-course of cognitive enhancement and the potential
cardiovascular and biochemical mechanisms of the cognitive enhancement. Another
study will examine the effect of 320 mg/day KeenMind for 6 months on cognitive
functioning in patients with Alzheimer's disease (additional study details not
provided). Another study is evaluating the effect of KeenMind or placebo on
6-14-year-old boys who have a high level of hyperactivity or inattention
(additional study details not provided). It is unclear when the studies that
are underway will be concluded and results published.
The
authors conclude that KeenMind is a safe and efficacious cognitive enhancer
based on the 10 years of research conducted at their facility. Although the
clinical evidence is strongest for bacopa's chronic cognitive-enhancing
effects, recent studies suggest it also has acute effects. Future research
should focus on the constituents responsible for the cognitive changes, and
longer duration trials are needed to determine whether bacopa may offer
protection against neurodegenerative disorders.
—Heather S. Oliff,
PhD
|